Quickly Spot Consensus Among the World’s Best Equity Analysts
| Name | Upside % |
Analysts bullish % |
|
|---|---|---|---|
|
47%
upside
6 price targets
|
0
%
|
|
|
|
40%
upside
18 price targets
|
0
%
|
|
|
|
40%
upside
13 price targets
|
0
%
|
|
|
4
Eli Lilly
LLY
$820B
|
40%
upside
7 price targets
|
0
%
|
|
|
38%
upside
21 price targets
|
0
%
|
|
|
|
38%
upside
8 price targets
|
0
%
|
|
|
|
33%
upside
9 price targets
|
0
%
|
|
|
|
33%
upside
4 price targets
|
0
%
|
|
|
|
30%
upside
20 price targets
|
0
%
|
|
|
|
29%
upside
5 price targets
|
0
%
|
|
|
11
AbbVie
ABBV
$356B
|
27%
upside
7 price targets
|
0
%
|
|
|
27%
upside
4 price targets
|
0
%
|
|
|
|
25%
upside
11 price targets
|
0
%
|
|
|
|
24%
upside
4 price targets
|
0
%
|
|
|
|
20%
upside
8 price targets
|
0
%
|
|
|
|
18%
upside
6 price targets
|
0
%
|
|
|
|
17%
upside
16 price targets
|
0
%
|
|
|
|
14%
upside
4 price targets
|
0
%
|
|
|
|
13%
upside
22 price targets
|
0
%
|
|
|
|
12%
upside
4 price targets
|
0
%
|
|
|
|
12%
upside
8 price targets
|
0
%
|
|
|
|
12%
upside
24 price targets
|
0
%
|
|
|
|
12%
upside
10 price targets
|
0
%
|
|
|
|
12%
upside
5 price targets
|
0
%
|
|
|
|
12%
upside
4 price targets
|
0
%
|
|